2 unknown. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 2 |
| Phase 1 | 1 | Unknown 1 |
Follow tipiracil: new trials by email Literature Review of tipiracil trials Research Report on tipiracil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 70 | 2022-10-01 | 2024-04-02 |
| Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab - Metastatic Colorectal Cancer | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 35 | 2022-08-01 | 2024-09-24 |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2)
China (2)
Yongkun Sun (2)